This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (118)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

Personalized Molecular Medicine

Lance A. Liotta, MD, PhD; Elise C. Kohn, MD; Emanuel F. Petricoin, PhD

JAMA. 2001;286:2211-2214.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

The cause of most human disease lies in the functional dysregulation of protein interactions. Proteomics, which includes the study of cellular protein interactions, has evolved from advances in scientific knowledge and technology. Understanding the role that protein networks play in disease will create enormous clinical opportunities, because these pathways represent the drug targets of the next decade. In the future, entire cellular networks, not just one dysregulated protein, will be the target of therapeutics. The next technologic leap will be the application of proteomic technologies to the bedside. Soon it will be possible to analyze the state of protein signal pathways in the disease-altered cells before, during, and after therapy, heralding the advent of true patient-tailored therapy.

Cellular Information and Protein Networks

The field of molecular medicine is moving beyond genomics to proteomics.^1-3 While DNA is the information archive, proteins do all . . . [Full Text of this Article]

Protein Circuitry Derangements as Disease Pathogenesis

New Microtechnologies for Protein Analysis

Protein-Targeted Therapy: Molecular Medicine's Next Opportunity

Patient-Tailored Therapeutics Using Proteomic Monitoring

Author Affiliations: National Cancer Institute, CCR, National Institutes of Health, Bethesda, Md (Drs Liotta and Kohn); and Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Md (Dr Petricoin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

November 14, 2001
JAMA. 2001;286(18):2337-2338.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular Imaging of Cardiovascular Disease
Jaffer et al.
Circulation 2007;116:1052-1061.
FULL TEXT  

Immunocell-array for Molecular Dissection of Multiple Signaling Pathways in Mammalian Cells
Zanardi et al.
Mol. Cell. Proteomics 2007;6:939-947.
ABSTRACT | FULL TEXT  

Population Proteomics: The Concept, Attributes, and Potential for Cancer Biomarker Research
Nedelkov et al.
Mol. Cell. Proteomics 2006;5:1811-1818.
ABSTRACT | FULL TEXT  

Proteomics in Clinical Trials and Practice: Present Uses and Future Promise
Azad et al.
Mol. Cell. Proteomics 2006;5:1819-1829.
ABSTRACT | FULL TEXT  

In This Issue: Communication in the Era of 'Personalized' Medicine
Stange and Acheson
Ann Fam Med 2006;4:194-196.
FULL TEXT  

Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis
Menard et al.
Cancer Res. 2006;66:1844-1850.
ABSTRACT | FULL TEXT  

Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling
Davidson et al.
Clin. Cancer Res. 2006;12:791-799.
ABSTRACT | FULL TEXT  

Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
Travis et al.
JNCI J Natl Cancer Inst 2006;98:15-25.
ABSTRACT | FULL TEXT  

Translational Research on the Way to Effective Therapy for Alzheimer Disease
Rosenberg
Arch Gen Psychiatry 2005;62:1186-1192.
ABSTRACT | FULL TEXT  

Genomic medicine: genetic variation and its impact on the future of health care
Willard et al.
Phil Trans R Soc B 2005;360:1543-1550.
ABSTRACT | FULL TEXT  

Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
Sheehan et al.
Mol. Cell. Proteomics 2005;4:346-355.
ABSTRACT | FULL TEXT  

Integrative Epidemiology: From Risk Assessment to Outcome Prediction
Spitz et al.
JCO 2005;23:267-275.
ABSTRACT | FULL TEXT  

Cancer of the Ovary
Cannistra
NEJM 2004;351:2519-2529.
FULL TEXT  

Informatics Platform for Global Proteomic Profiling and Biomarker Discovery Using Liquid Chromatography-Tandem Mass Spectrometry
Radulovic et al.
Mol. Cell. Proteomics 2004;3:984-997.
ABSTRACT | FULL TEXT  

Metabolomics in the Opening Decade of the 21st Century: Building the Roads to Individualized Health
German et al.
J. Nutr. 2004;134:2729-2732.
ABSTRACT | FULL TEXT  

Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer
Aljada et al.
JCO 2004;22:3218-3229.
ABSTRACT | FULL TEXT  

Differential Expression of S100C in Thyroid Lesions
Torres-Cabala et al.
INT J SURG PATHOL 2004;12:107-115.
ABSTRACT  

Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004.
Geho et al.
Clin. Cancer Res. 2004;10:825-827.
FULL TEXT  

Clinical Applications of Proteomics
Petricoin and Liotta
J. Nutr. 2003;133:2476S-2484.
ABSTRACT | FULL TEXT  

Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes
Poon et al.
Clin. Chem. 2003;49:752-760.
ABSTRACT | FULL TEXT  

Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Danesi et al.
Pharmacol. Rev. 2003;55:57-103.
ABSTRACT | FULL TEXT  

Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects
Evans and McLeod
NEJM 2003;348:538-549.
FULL TEXT  

Prevention of Ovarian Cancer: Intraepithelial Neoplasia
Brewer et al.
Clin. Cancer Res. 2003;9:20-30.
ABSTRACT | FULL TEXT  

Molecular Diagnostics
Braziel et al.
ASH Education Book 2003;2003:279-293.
ABSTRACT | FULL TEXT  

Toward a Human Blood Serum Proteome: Analysis By Multidimensional Separation Coupled With Mass Spectrometry
Adkins et al.
Mol. Cell. Proteomics 2002;1:947-955.
ABSTRACT | FULL TEXT  

Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy
Booth et al.
J. Appl. Physiol. 2002;93:3-30.
ABSTRACT | FULL TEXT